HS
MDGL icon

HighVista Strategies’s Madrigal Pharmaceuticals MDGL Stock Holding History

HighVista Strategies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
2,852
+254
+10% +$130K 0.35% 85
2026
Q1 		$1.36M Sell
2,598
-241
-8% -$115K 0.38% 85
2025
Q4 		$1.65M Sell
2,839
-698
-20% -$357K 0.43% 65
2025
Q3 		$1.62M Buy
3,537
+1,232
+53% +$460K 0.4% 79
2025
Q2 		$698K Buy
2,305
+94
+4% +$28K 0.26% 116
2025
Q1 		$732K Hold
2,211
– – 0.28% 119
2024
Q4 		$682K Hold
2,211
– – 0.25% 117
2024
Q3 		$469K Sell
2,211
-323
-13% -$82.6K 0.16% 133
2024
Q2 		$710K Hold
2,534
– – 0.26% 108
2024
Q1 		$677K Buy
2,534
+1,103
+77% +$260K 0.24% 108
2023
Q4 		$331K Sell
1,431
-1,614
-53% -$282K 0.12% 124
2023
Q3 		$445K Buy
3,045
+249
+9% +$46.9K 0.21% 120
2023
Q2 		$646K Hold
2,796
– – 0.3% 110
2023
Q1 		$677K Buy
+2,796
New +$762K 0.55% 63
2022
Q4 		– Sell
-9,527
Closed -$619K – 117
2022
Q3 		$619K Buy
9,527
+4,727
+98% +$328K 0.35% 74
2022
Q2 		$344K Buy
4,800
+275
+6% +$20.2K 0.21% 88
2022
Q1 		$444K Buy
+4,525
New +$382K 0.28% 76

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's MDGL Position: Q2 2026 in Review

HighVista Strategies increased its Madrigal Pharmaceuticals (MDGL) stake by 9.8% in Q2 2026, buying an estimated $130K and bringing the position to 2,852 shares worth $1.53M. The position accounts for 0.35% of the portfolio, ranked #85.

HighVista Strategies first reported a position in MDGL in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.65M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • HighVista Strategies held 2,852 shares of Madrigal Pharmaceuticals worth $1.53M as of Q2 2026.
  • HighVista Strategies bought 254 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $130K.
  • Madrigal Pharmaceuticals made up 0.35% of HighVista Strategies's portfolio in Q2 2026, its #85 holding.
  • HighVista Strategies first reported a position in Madrigal Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • HighVista Strategies's Madrigal Pharmaceuticals position peaked at $1.65M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.